The aim of this project will be to synthesize, develop and test CurCaP: a novel material that can be used for both bone replacement and as carrier for drug delivery that allows for local, controlled and slow release of anticancer compounds, for use in cancer treatment and bone replacement (in the bony area after tumor removal). Each year, many patients suffer from tumors in or near the bone, due to various primary forms of cancer or metastases. During treatment, the tumors and a part of the bone are removed, which often requires local bone replacement, combined with additional anti-cancer treatment (radiation, chemotherapy). However, cancers in the bone are often resistant to chemotherapy; there is an unmet need for effective treatment options. The CurCaP to be developed builds on an existing patented protocol for a biodegradable CaP-scaffold (BioCaP), developed by Dr. Liu. This BioCaP scaffold is unique in being an excellent bone substitute, while at the same time designed for integration of (bio)active molecules, acting locally by slow release. In this project, the group of Dr. Liu, ACTA, will use and adapt this method to integrate an anticancer compound (produced in Guangdong, China), taking into account the required specifications for structure, loading and release kinetics. Detailed chemical, structural and composition analysis for the resulting material will be performed at the South China University of Technology (SCUoT) in the group of Prof. Dr. Chang Du, using the expertise and analysis methods relating to the anticancer agent and nanoparticle biomaterials available. The performance of the novel CurCaP particles will be assessed in in vitro cell models and in vivo. This project will result in the availability of the well-characterized CurCaP anticancer-bone repair medical device, its synthesis protocol, and first performance data package. This will enable larger-scale clinical grade synthesis, testing of CurCaP in clinical setting and registration (after this project).